FR2413974B1 - - Google Patents

Info

Publication number
FR2413974B1
FR2413974B1 FR7800305A FR7800305A FR2413974B1 FR 2413974 B1 FR2413974 B1 FR 2413974B1 FR 7800305 A FR7800305 A FR 7800305A FR 7800305 A FR7800305 A FR 7800305A FR 2413974 B1 FR2413974 B1 FR 2413974B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7800305A
Other languages
French (fr)
Other versions
FR2413974A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2413974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to FR7800305A priority Critical patent/FR2413974A1/fr
Priority to DE7878400265T priority patent/DE2860970D1/de
Priority to EP19780400265 priority patent/EP0003089B1/fr
Publication of FR2413974A1 publication Critical patent/FR2413974A1/fr
Application granted granted Critical
Publication of FR2413974B1 publication Critical patent/FR2413974B1/fr
Granted legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
FR7800305A 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie Granted FR2413974A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie
DE7878400265T DE2860970D1 (en) 1978-01-06 1978-12-27 Drier for silkscreen printed sheets
EP19780400265 EP0003089B1 (fr) 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Publications (2)

Publication Number Publication Date
FR2413974A1 FR2413974A1 (fr) 1979-08-03
FR2413974B1 true FR2413974B1 (enrdf_load_html_response) 1982-12-03

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7800305A Granted FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Country Status (3)

Country Link
EP (1) EP0003089B1 (enrdf_load_html_response)
DE (1) DE2860970D1 (enrdf_load_html_response)
FR (1) FR2413974A1 (enrdf_load_html_response)

Families Citing this family (444)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
IL126383A0 (en) 1996-04-01 1999-05-09 Genentech Inc Apo-2li and apo-3 apoptosis polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
JP3394540B2 (ja) 1997-01-31 2003-04-07 ジェネンテク・インコーポレイテッド Ｏ−フコシルトランスフェラーゼ
WO1998056808A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
JP2001520885A (ja) 1997-10-29 2001-11-06 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導遺伝子
DK1481990T3 (da) 1997-11-21 2007-10-01 Genentech Inc A33-beslægtede antigener og deres farmakologiske anvendelser
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU736506B2 (en) 1997-12-03 2001-07-26 Genentech Inc. Polypeptides and nucleic acids encoding the same
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
AU2325199A (en) 1998-01-15 1999-08-02 Genentech Inc. Apo-2 ligand
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
IL144056A0 (en) 1999-01-15 2002-04-21 Genentech Inc Polypeptide variants with altered effector function
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN101518653B (zh) 1999-06-25 2015-08-19 基因技术股份有限公司 使用抗ErbB抗体-类美坦素偶联物的治疗方法
MXPA02002037A (es) 1999-08-27 2002-10-31 Genentech Inc Dosificaciones para el tratamiento con anticuerpos anti-erb2.
EP1661997A1 (en) 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DK1246917T3 (da) 2000-01-13 2009-06-08 Genentech Inc Humane Stra6-polypeptider
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
NZ530985A (en) 2001-08-29 2006-03-31 Genentech Inc Bv8 nucleic acids and polypeptides with mitogenic activity
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
ES2436206T3 (es) 2001-11-14 2013-12-27 Janssen Biotech, Inc. Anticuerpos anti il-6, composiciones, métodos y usos
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
JP2005525095A (ja) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003273218C1 (en) 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
JP5303092B2 (ja) 2002-09-11 2013-10-02 ジェネンテック， インコーポレイテッド タンパク質精製
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP2311875A1 (en) 2003-05-30 2011-04-20 Genentech, Inc. Treatment with anti-VEGF antibodies
ES2538469T3 (es) 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
WO2004112572A2 (en) 2003-06-13 2004-12-29 University Of Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
ES2786568T3 (es) 2003-07-28 2020-10-13 Genentech Inc Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
AP2006003670A0 (en) 2003-12-23 2006-06-30 Rinat Neuroscience Corp Agonist anti-TRKC antibodies and methods using same
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
ES2339789T3 (es) 2004-07-20 2010-05-25 Genentech, Inc. Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
EP1869184B1 (en) 2005-04-11 2011-09-28 National Research Council Of Canada Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
EP2267450B1 (en) 2005-04-29 2015-01-28 The Regents of The University of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
HRP20130400T1 (en) 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
LT2573114T (lt) 2005-08-10 2016-10-10 Macrogenics, Inc. Atpažinimas ir konstravimas antikūnų su variantinėmis fc sritimis ir jų panaudojimo būdai
ES2664421T3 (es) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
PL3219328T3 (pl) 2005-12-29 2020-12-14 Janssen Biotech, Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposób i zastosowania
BRPI0706840A2 (pt) 2006-01-05 2011-04-05 Genentech Inc anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
CA2642419A1 (en) 2006-02-06 2007-08-16 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK1989231T3 (en) 2006-03-21 2015-08-24 Genentech Inc COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2390666A1 (en) 2006-03-21 2011-11-30 The Regents of The University of California N-Cadherin as target for cancer diagnosis and therapy
SG170728A1 (en) 2006-03-23 2011-05-30 Novartis Ag Anti-tumor cell antigen antibody therapeutics
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP2009536526A (ja) 2006-05-04 2009-10-15 ジェネンテック・インコーポレーテッド Ｚｐａポリペプチドに関連する方法および組成物
EP2446904B1 (en) 2006-05-30 2015-04-29 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
JP2010505743A (ja) 2006-06-01 2010-02-25 ジェネンテック インコーポレイテッド ＣＲＩｇ及びＣ３ｂ：ＣＲＩｇ複合体の結晶構造
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
CN104059149B (zh) 2006-08-22 2017-04-12 诺沃诺蒂斯克股份有限公司 具有改进性能的抗‑C5aR抗体
JP2010501172A (ja) 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 肺癌に対する予後マーカーおよび治療標的
US9505821B2 (en) 2006-10-03 2016-11-29 Rutgers, The State University Of New Jersey ATAP peptides, nucleic acids encoding the same and associated methods of use
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
CA2670320A1 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
EP2104513B1 (en) 2006-11-27 2015-05-20 diaDexus, Inc. Ovr110 antibody compositions and methods of use
ES2379413T3 (es) 2007-02-22 2012-04-25 Genentech, Inc. Procedimientos para detectar la enfermedad inflamatoria del intestino
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
EP2173381B1 (en) 2007-05-14 2013-10-02 NovImmune SA Fc receptor-binding polypeptides with modified effector functions
CA2689302C (en) 2007-06-08 2015-08-25 Australian Poultry Crc Pty Ltd. Clostridial toxin netb
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
ES3022264T3 (en) 2007-07-09 2025-05-28 Hoffmann La Roche Prevention of disulfide bond reduction during recombinant production of polypeptides
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
WO2009046123A2 (en) 2007-10-02 2009-04-09 Genentech, Inc. Nlrr-1 antagonists and uses thereof
CN103142999A (zh) 2007-11-07 2013-06-12 健泰科生物技术公司 用于治疗微生物病症的组合物和方法
KR20110015409A (ko) 2007-11-29 2011-02-15 제넨테크, 인크. 염증성 장 질환에 대한 유전자 발현 마커
EP3189831A1 (en) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
AU2008337100B2 (en) 2007-12-17 2013-02-28 Pfizer Limited Treatment of interstitial cystitis
US7982017B2 (en) 2007-12-18 2011-07-19 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
MX2010011088A (es) 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
KR101361905B1 (ko) 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
RU2530583C2 (ru) 2008-09-10 2014-10-10 Дженентек, Инк. Способы ингибирования глазного ангиогенеза
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2358734A1 (en) 2008-12-16 2011-08-24 Millipore Corporation Purification of proteins
SG172219A1 (en) 2008-12-17 2011-07-28 Genentech Inc Hepatitis c virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP2382234A2 (en) 2008-12-23 2011-11-02 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
EP2757160A3 (en) 2009-07-20 2014-07-30 Genentech, Inc. Gene expression markers for Crohn's disease
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
AU2010292897B2 (en) 2009-08-06 2016-01-07 Genentech, Inc. Method to improve virus removal in protein purification
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
US20110038871A1 (en) 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
PL2464725T5 (pl) 2009-08-11 2025-04-28 F. Hoffmann-La Roche Ag Wytwarzanie białek w wolnych od glutaminy pożywkach do hodowli komórkowej
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
US20120207770A1 (en) 2009-10-14 2012-08-16 Nanyang Technological University Antiproliferative agent
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
MX2012005168A (es) 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
CA2780319A1 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
US8779108B2 (en) 2009-11-24 2014-07-15 Medimmune, Limited Targeted binding agents against B7-H1
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
EP3616719A1 (en) 2009-12-21 2020-03-04 F. Hoffmann-La Roche AG Antibody formulation
EP2516465B1 (en) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antibodies and uses thereof
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
KR101838763B1 (ko) 2010-02-18 2018-03-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 인테그린 αⅤβ8 중화 항체
RU2595389C2 (ru) 2010-02-23 2016-08-27 Дженентек, Инк. Композиции и способы для диагностики и лечения опухолей
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EA031203B1 (ru) 2010-03-30 2018-11-30 Янссен Байотек Инк. Гуманизированные антитела к il-25
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011146394A1 (en) 2010-05-17 2011-11-24 Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
KR101869987B1 (ko) 2010-05-28 2018-07-20 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
WO2011153380A2 (en) 2010-06-02 2011-12-08 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP3323830B1 (en) 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
CA2809837C (en) 2010-08-31 2019-12-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2685968A1 (en) 2011-03-15 2014-01-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
RU2595836C2 (ru) 2011-03-31 2016-08-27 Дженентек, Инк. Способы введения антагонистов интегрина бета7
KR102001686B1 (ko) 2011-04-07 2019-07-18 암젠 인크 신규한 egfr 결합 단백질
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
KR20140091721A (ko) 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2859472A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
JP6684490B2 (ja) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
DK2817338T3 (en) 2012-02-24 2017-10-23 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
EP2844674A1 (en) 2012-05-04 2015-03-11 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP2847230B1 (en) 2012-05-10 2020-08-12 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
HK1208499A1 (en) 2012-06-11 2016-03-04 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
DK2877494T3 (da) 2012-07-23 2020-09-21 La Jolla Inst Allergy & Immunology PTPRS og proteoglycaner i autoimmun sygdom
JP2015529236A (ja) 2012-09-25 2015-10-05 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリンの精製
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
PL2903691T3 (pl) 2012-10-05 2019-10-31 Hoffmann La Roche Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
JP6392770B2 (ja) 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
BR112015018851A2 (pt) 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
PL2958944T3 (pl) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
JP6389236B2 (ja) 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド 酸化還元製剤
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
AR095396A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones de anticuerpo
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
AU2014233393B2 (en) 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
CN105392882A (zh) 2013-04-19 2016-03-09 加利福尼亚大学董事会 孤星病毒
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
JP6462681B2 (ja) 2013-07-12 2019-01-30 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィーのインプットの最適化の解明
LT3021869T (lt) 2013-07-16 2020-10-12 F. Hoffmann-La Roche Ag Vėžio gydymo būdai, naudojant pd-1 ašį surišančius antagonistus ir tigit inhibitorius
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
RU2016111139A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
KR20210123433A (ko) 2013-08-29 2021-10-13 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
MY176522A (en) 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
TWI736515B (zh) 2013-11-13 2021-08-21 美商輝瑞大藥廠 類腫瘤壞死因子之配體１ａ之專一性抗體及其組合物及用途
AU2014357521B2 (en) 2013-12-02 2018-10-11 Baylor College Of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20160089532A (ko) 2013-12-17 2016-07-27 제넨테크, 인크. Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
MX389667B (es) 2013-12-17 2025-03-20 Genentech Inc Antagonistas de unión al eje pd-1 y taxanos para usarse en el tratamiento de cáncer.
CA3190821A1 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
PT3119431T (pt) 2014-03-21 2024-04-16 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o peptídeo relacionado com o gene da calcitonina e métodos de utilização dos mesmos
EP3122377A4 (en) 2014-03-27 2018-03-14 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
WO2015161267A2 (en) 2014-04-18 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
KR102366644B1 (ko) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체 (egfr) 항체
JP2017522289A (ja) 2014-06-17 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたα−Ｖβ−８抗体
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
MX2017004311A (es) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
MX384534B (es) 2014-11-05 2025-03-14 Genentech Inc Metodos de produccion de proteinas de cadena doble en bacterias.
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US10689423B2 (en) 2015-01-13 2020-06-23 City Of Hope CTLA4-binding protein peptide-linker masks
EP3795168A1 (en) 2015-01-16 2021-03-24 City of Hope Cell penetrating antibodies
TWI710571B (zh) 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
AU2016222683A1 (en) 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
JP6976854B2 (ja) 2015-03-30 2021-12-08 シティ・オブ・ホープCity of Hope 機械的にかみ合った複合体
CN107106671B (zh) 2015-04-03 2022-01-14 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
WO2016164835A1 (en) 2015-04-08 2016-10-13 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
DK4234581T3 (da) 2015-04-13 2025-10-06 Pfizer Inc Terapeutiske antistoffer og deres anvendelse
CA2984608A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
CN114990141A (zh) 2015-05-15 2022-09-02 希望之城 嵌合抗原受体组合物
CA2984638A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN108135958B (zh) 2015-08-06 2022-03-04 希望之城 细胞穿透蛋白-抗体缀合物及其使用方法
WO2017041004A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
DK3359572T3 (da) 2015-10-06 2025-01-27 Hoffmann La Roche Fremgangsmåde til behandling af multipel sklerose
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
CA3007997A1 (en) 2015-12-10 2017-06-15 City Of Hope Cell penetrating cyanine-coupled antibodies
MX391382B (es) 2015-12-24 2025-03-21 Corvus Pharmaceuticals Inc Métodos de tratamiento de cáncer
KR102796135B1 (ko) 2015-12-30 2025-04-16 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
KR20180093078A (ko) 2015-12-30 2018-08-20 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체의 용도
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
TW201936640A (zh) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 對表皮生長因子受體變異體ｉｉｉ具特異性之抗體類及彼等之用途
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
MA44510A (fr) 2016-03-29 2021-03-31 Janssen Biotech Inc Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
EP3436046A4 (en) 2016-04-01 2020-03-11 The Regents of The University of California INTEGRIN ALPHA 5 BETA 1 INHIBITORS AND METHODS OF USE
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20190005966A (ko) 2016-05-10 2019-01-16 제넨테크, 인크. 폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을 감소시키기 위한 방법
MX2018015173A (es) 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
WO2018018039A2 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
KR102617148B1 (ko) 2016-08-15 2023-12-26 제넨테크, 인크. 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018048939A1 (en) 2016-09-06 2018-03-15 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
CA3037144A1 (en) 2016-09-16 2018-03-22 Shanghai Henlius Biotech, Inc. Anti-pd-1 antibodies
EP3515937A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
WO2018055573A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
US20190225701A1 (en) 2016-09-26 2019-07-25 The Brigham And Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
IL316408A (en) 2016-09-30 2025-01-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
CA3040812A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
EP3538101B1 (en) 2016-11-14 2024-06-19 Virginia Commonwealth University Inhibitors of cancer and/or metastasis
EP3541422A4 (en) 2016-11-16 2020-05-06 Janssen Biotech, Inc. METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018127791A2 (en) 2017-01-06 2018-07-12 Biosion, Inc. Erbb2 antibodies and uses therefore
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
CN110431152A (zh) 2017-03-03 2019-11-08 雷纳神经科学公司 抗gitr抗体及其使用方法
US11726091B2 (en) 2017-04-03 2023-08-15 The Regents Of The University Of California Compositions and methods of diagnosing pancreatic cancer
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615574A4 (en) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. CONSTRUCTIONS SPECIFICALLY RECOGNIZING GLYPICANE 3 AND USES OF SUCH LATEST
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP7220161B2 (ja) 2017-05-26 2023-02-09 ノビミューン エスアー 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
PE20242042A1 (es) 2017-06-02 2024-10-10 Pfizer Anticuerpos especificos para flt3 y sus usos
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
AU2018360789A1 (en) 2017-11-06 2020-05-14 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL-23 specific antibody
PE20251579A1 (es) 2018-02-01 2025-06-16 Pfizer Anticuerpos especificos para cd70 y sus usos
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CN112105350A (zh) 2018-03-13 2020-12-18 加利福尼亚大学董事会 整联蛋白α2β1的抑制剂和使用方法
CN112334484A (zh) 2018-03-14 2021-02-05 诺维莫尼公司 抗-CD3ε抗体及其应用方法
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
JP2021527693A (ja) 2018-06-21 2021-10-14 ユマニティ セラピューティクス，インコーポレーテッド 神経学的障害の治療及び予防のための組成物及び方法
TWI819011B (zh) 2018-06-23 2023-10-21 美商建南德克公司 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
CN112638478B (zh) 2018-06-29 2025-08-15 希望之城公司 用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
KR20210034622A (ko) 2018-07-18 2021-03-30 제넨테크, 인크. Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
BR112021002130A2 (pt) 2018-08-08 2021-05-04 Genentech, Inc. formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
EP3877407A1 (en) 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
SG11202111345PA (en) 2019-04-19 2021-11-29 Chugai Pharmaceutical Co Ltd Chimeric receptor that recognizes engineered site in antibody
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN114341187A (zh) 2019-07-12 2022-04-12 中外制药株式会社 抗突变型fgfr3抗体及其用途
JP7644087B2 (ja) 2019-07-26 2025-03-11 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP4103602A1 (en) 2020-02-11 2022-12-21 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
US20210347880A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
EP4153220A4 (en) 2020-05-21 2024-09-11 Janssen Biotech, Inc. METHOD OF TREATING INFLAMMATORY BOWEL DISEASE BY MEANS OF COMBINATION THERAPY OF ANTIBODIES DIRECTED AGAINST IL-23 AND TNF ALPHA
AU2021293038A1 (en) 2020-06-16 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating triple-negative breast cancer
US20220025035A1 (en) 2020-07-13 2022-01-27 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
EP4182346A1 (en) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutic antibodies and their uses
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
AU2022210221A1 (en) 2021-01-20 2023-08-31 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
WO2022190033A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US20220289834A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
IL305827A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
US20220315654A1 (en) 2021-03-22 2022-10-06 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
EP4426730A1 (en) 2021-11-05 2024-09-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
JP2024544555A (ja) 2021-11-15 2024-12-03 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病を処置する方法
AU2022396102A1 (en) 2021-11-23 2024-07-11 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
CN119562970A (zh) 2022-03-18 2025-03-04 进化免疫治疗公司 双特异性抗体融合分子及其使用方法
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
US20230364020A1 (en) 2022-04-01 2023-11-16 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
WO2023212483A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
KR20250111179A (ko) 2022-11-22 2025-07-22 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
CN117190671B (zh) * 2023-09-13 2025-08-26 莱阳银通纸业有限公司 一种种子纸快速风干设备及方法
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025114357A1 (en) 2023-11-28 2025-06-05 Novimmune Sa Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
US20250296998A1 (en) 2024-03-20 2025-09-25 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Also Published As

Publication number Publication date
EP0003089A1 (fr) 1979-07-25
EP0003089B1 (fr) 1981-08-12
FR2413974A1 (fr) 1979-08-03
DE2860970D1 (en) 1981-11-12

Similar Documents

Publication Publication Date Title
FR2413974B1 (enrdf_load_html_response)
FR2413132B1 (enrdf_load_html_response)
FR2414552B1 (enrdf_load_html_response)
FR2415429B1 (enrdf_load_html_response)
FR2415955B1 (enrdf_load_html_response)
FR2415739B1 (enrdf_load_html_response)
FR2415100B1 (enrdf_load_html_response)
FR2415219B1 (enrdf_load_html_response)
FR2413224B1 (enrdf_load_html_response)
FR2415595B1 (enrdf_load_html_response)
FR2416953B1 (enrdf_load_html_response)
FR2414971B3 (enrdf_load_html_response)
FR2416748B1 (enrdf_load_html_response)
FR2416079B1 (enrdf_load_html_response)
FR2417049B1 (enrdf_load_html_response)
DK129178A (enrdf_load_html_response)
DK168678A (enrdf_load_html_response)
AU73950S (enrdf_load_html_response)
BG25940A1 (enrdf_load_html_response)
BG25952A1 (enrdf_load_html_response)
BG25858A1 (enrdf_load_html_response)
BG25872A1 (enrdf_load_html_response)
BG25898A1 (enrdf_load_html_response)
BG25902A1 (enrdf_load_html_response)
BG25857A1 (enrdf_load_html_response)

Legal Events

Date Code Title Description
TP Transmission of property
CL Concession to grant licenses
ST Notification of lapse